恶性疾病中的纤溶活性。
Fibrinolytic activity in malignant disease.
作者信息
Rennie J A, Ogston D
出版信息
J Clin Pathol. 1975 Nov;28(11):872-4. doi: 10.1136/jcp.28.11.872.
Abstract
Resting fibrinolytic activity and fibrinolytic capacity were compared in 31 patients with malignant disease and in 24 control subjects without malignant disease. Patients with malignant disease had a lower mean fibrinolytic activity: this was particularly marked in those with disseminated disease. In contrast, patients with malignant disease had a fibrinolytic capacity which did not differ from that of the control subjects.
摘要
对31例恶性疾病患者和24例无恶性疾病的对照者的静息纤溶活性和纤溶能力进行了比较。恶性疾病患者的平均纤溶活性较低：这在播散性疾病患者中尤为明显。相比之下，恶性疾病患者的纤溶能力与对照者并无差异。
相似文献
1
Fibrinolytic activity in malignant disease.恶性疾病中的纤溶活性。
J Clin Pathol. 1975 Nov;28(11):872-4. doi: 10.1136/jcp.28.11.872.
2
Response of fibrinolytic activity to venous occlusion.纤溶活性对静脉闭塞的反应。
Br Med J. 1975 Sep 6;3(5983):571-3. doi: 10.1136/bmj.3.5983.571.
3
Fibrinolytic activity of the human peritoneum.
Eur Surg Res. 1980;12(6):433-8. doi: 10.1159/000128151.
4
The role of hemostasis and fibrinolysis in the metastatic spread of cancer.止血与纤溶在癌症转移扩散中的作用。
Semin Thromb Hemost. 1984 Jan;10(1):61-70. doi: 10.1055/s-2007-1004408.
5
6
A study on the fibrinolytic activity of cadaveric blood: isolation and characterization of plasminogen activator from cadaveric plasma after sudden death.
Nihon Hoigaku Zasshi. 1984 Jun;38(3):280-8.
7
[Tissue plasminogen activator activity in early prostatic cancer and in bone metastases of prostatic cancer].
Wien Klin Wochenschr. 1984 Sep 14;96(17):658-61.
8
9
[Pathogenesis of hemostasis disorders in malignant neoplasms].[恶性肿瘤中止血障碍的发病机制]
Vopr Onkol. 1984;30(4):43-7.
10
Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.采用纤维蛋白和非纤维蛋白检测法测定人肿瘤组织及相邻正常组织中的纤溶酶原激活物含量。
Cancer Res. 1986 Apr;46(4 Pt 1):1788-94.
引用本文的文献
1
Role of P-selectin in thromboembolic events in patients with cancer.P-选择素在癌症患者血栓栓塞事件中的作用。
Mol Clin Oncol. 2018 Jan;8(1):188-196. doi: 10.3892/mco.2017.1482. Epub 2017 Nov 2.
2
Identification of a plasminogen activator derived from nasopharyngeal carcinoma.源自鼻咽癌的纤溶酶原激活剂的鉴定。
Eur Arch Otorhinolaryngol. 1990;247(6):374-8. doi: 10.1007/BF00179011.
3
The plasminogen-plasmin system in malignancy.恶性肿瘤中的纤溶酶原-纤溶酶系统
Cancer Metastasis Rev. 1992 Nov;11(3-4):291-311. doi: 10.1007/BF01307184.
本文引用的文献
1
Fibrinolysis in metastatic cancer of the prostate.
Cancer. 1952 Jan;5(1):9-12. doi: 10.1002/1097-0142(195201)5:1<9::aid-cncr2820050104>3.0.co;2-s.
2
FIBRINOLYSIS AND CARCINOMA OF THE PROSTATE.纤维蛋白溶解与前列腺癌
J Clin Pathol. 1965 May;18(3):330-3. doi: 10.1136/jcp.18.3.330.
3
The histological localisation of fibrinolysin activator.纤维蛋白溶酶激活剂的组织学定位。
J Pathol Bacteriol. 1959 Jul;78:281-3. doi: 10.1002/path.1700780131.
4
Studies on enhanced fibrinolytic activity in man.关于人类纤维蛋白溶解活性增强的研究。
J Clin Invest. 1959 May;38(5):810-22. doi: 10.1172/JCI103863.
5
Urokinase an activator of plasminogen from human urine. I. Isolation and properties.尿激酶——一种源自人尿的纤溶酶原激活剂。I. 分离与特性
Biochim Biophys Acta. 1957 May;24(2):278-82. doi: 10.1016/0006-3002(57)90194-4.
6
The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate.前列腺转移性癌患者发生纤维蛋白溶解的意义。
Cancer. 1953 Jan;6(1):63-7. doi: 10.1002/1097-0142(195301)6:1<63::aid-cncr2820060105>3.0.co;2-l.
7
The fibrinolytic enzyme system in hepatic cirrhosis and malignant metastases.肝硬化和恶性转移中的纤维蛋白溶解酶系统。
J Clin Pathol. 1971 Dec;24(9):822-6. doi: 10.1136/jcp.24.9.822.
8
"Fibrinolytic capacity" in healthy volunteers as estimated from effect of venous occlusion of arms.
Acta Chir Scand. 1972;138(5):429-36.
9
Coagulation disorders in cancer. 3. Fibrinolysis and inhibitors.
Cancer. 1970 Apr;25(4):867-74. doi: 10.1002/1097-0142(197004)25:4<867::aid-cncr2820250417>3.0.co;2-c.
10
Fibrinolytic activity of human veins.人静脉的纤溶活性。
Lancet. 1967 Jul 15;2(7507):127-8. doi: 10.1016/s0140-6736(67)92964-9.
Zotero 插件